stockportfolio.pro
Veracyte, Inc. P/E Ratio 2011–2025
Veracyte, Inc. (VCYT) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -6.3%/yr over 14 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 51.34 | -59.8% |
| FY 2024 | 127.74 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: Veracyte, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Veracyte, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVeracyte, Inc. — frequently asked questions
What is Veracyte, Inc.'s price-to-earnings ratio?
Veracyte, Inc. (VCYT) reported price-to-earnings ratio of 51.34 for fiscal year 2025, per its SEC filings.
How has Veracyte, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, VCYT's price-to-earnings ratio declined at roughly 6.3% per year (compound annual rate), from 127.74 to 51.34.
Where does this data come from?
Figures are computed from Veracyte, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.